ANASCORP (Rare Disease Therapeutics, Inc)
Welcome to the PulseAid listing for the ANASCORP drug offered from Rare Disease Therapeutics, Inc. This Antivenin [EPC],Passively Acquired Immunity [PE],Venom Neutralization [MoA],Antivenins [Chemical/Ingredient] pharmaceutical is classified as a PLASMA DERIVATIVE. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same PLASMA DERIVATIVE drug type category.
LABELER NAME / MANUFACTURER: | Rare Disease Therapeutics, Inc |
NON-PROPRIETARY NAME: | CENTRUROIDES (Scorpion) IMMUNE F(ab)2 (EQUINE) |
SUBSTANCE NAME: | CENTRUROIDES FAB2 ANTIVENIN (EQUINE) |
TYPE: | PLASMA DERIVATIVE |
PHARMA CLASS: | Antivenin [EPC],Passively Acquired Immunity [PE],Venom Neutralization [MoA],Antivenins [Chemical/Ingredient] |
ROUTE: | INTRAVENOUS |
DOSAGE FORM: | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION |
MARKETING CATEGORY NAME: | BLA |
START MARKETING DATE: | 2011-08-03 |
END MARKETING DATE: | 0000-00-00 |
ANASCORP PLASMA DERIVATIVE Details:
Item Description | ANASCORP from Rare Disease Therapeutics, Inc |
LABELER NAME: | Rare Disease Therapeutics, Inc |
DEA SCHEDULE: |
|
ACTIVE STRENGTH: | 24(mg/mL) |
START MARKETING DATE: | 2011-08-03 |
END MARKETING DATE: | 0000-00-00 |
PRODUCT ID: | 66621-0150_c8f00dc0-684c-4389-86d5-b566709205f1 |
PRODUCT NDC: | 66621-0150 |
APPLICATION NUMBER: | BLA125335 |
Other CENTRUROIDES FAB2 ANTIVENIN (EQUINE) Pharmaceutical Manufacturers / Labelers: